U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07923630) titled 'Validation & Intervention Testing for Aging, Longevity and Healthspan' on Oct. 26.
Brief Summary: The study aims to address the gap between lifespan and healthspan (years of life free of age-related diseases and disabilities) by testing whether 2 approved U.S Food and Drug Administration (FDA) medications, dapagliflozin and semaglutide, can help people stay healthier as they age and delay the age-related functional decline. The study will test these medications over 36 months of treatment plus 6 months of observational follow up to see if they can safely maintain health and function during aging and eventually support their use for e...